Participated · Equity · Jul 2026

Pearl Health builds an AI-driven platform that identifies at-risk Medicare patients, predicts risk, orchestrates workflows, and automates administrative actions to improve outcomes and lower total cost of care. The company emphasizes Performance Intelligence and is developing Care Orchestration AI agents to automate tasks like annual wellness visit scheduling, post-discharge follow-ups, and care management outreach. Pearl supports over 10,000 providers across more than 40 states and cares for over 250,000 Medicare beneficiaries, managing about $3.6 billion in annualized medical spend. Founded in 2020, Pearl reached profitability in 2025 and is projecting significant growth, including tripling its patient base from 2024 through the end of 2026 and delivering $500 million in projected gross savings. The company plans to use the new equity and debt capital to expand its AI platform, deepen enterprise and payer partnerships, enter Medicare Advantage, and launch new risk offerings.

Led · Series E · Jun 2026

GT Medical Technologies develops GammaTile, an FDA-cleared bioresorbable radiation-emitting implant placed at the time of brain tumor resection to deliver immediate, localized radiation to the surgical bed. The company highlights pivotal ROADS Phase 3 randomized controlled trial results presented at ASCO 2026 showing a 12-month surgical bed recurrence rate of 1.3% with GammaTile versus 15.4% with standard of care and improved survival outcomes. GT recently initiated the BRIDGES randomized controlled trial in newly diagnosed glioblastoma patients and plans to use proceeds from its Series E financing to expand that trial and scale commercial and operational efforts. The company was founded by a team of tumor specialists and announced the Series E from Tempe, Arizona. GT positions GammaTile as eliminating the delay between surgery and postoperative radiation by delivering immediate treatment at the resection site. The firm states the clinical data and new financing support its goal of broader adoption and further clinical development.

Participated · Series B · Jun 2026

City Therapeutics is developing a pipeline of RNA interference (RNAi) therapeutics using a next‑generation RNAi engineering platform. The company has initiated a Phase 1 clinical trial of CITY‑FXI targeting Factor XI and reported positive preclinical data for CITY‑RBP4, a candidate for Stargardt disease. It has announced strategic collaborations with Bausch + Lomb and Biogen and plans to advance two programs to clinical stage this year while progressing additional programs toward the clinic by year‑end 2026. City Therapeutics is based in Cambridge, MA, and has raised over $230 million from life sciences investors to date. The recent $99.5 million Series B is intended to accelerate its platform, expand the pipeline, and support business development and partnership activities.

Participated · Equity · Jun 2026

AlphaSense offers an enterprise AI platform that combines domain-specific AI with a proprietary content library of more than 500 million business documents to deliver market intelligence and workflow automation. The company serves over 7,000 global enterprises and now covers more than 70% of S&P 500 companies, including major firms across technology, finance, and consumer sectors. AlphaSense has introduced AI capabilities such as SuperAnalyst, Generative Search, Generative Grid, and Deep Research to automate high-value financial and strategic workflows. Financially, AlphaSense reported surpassing $600 million in annual recurring revenue in Q1 2026, up from $500 million in October 2025. The company has more than doubled headcount in EMEA and APAC and recently opened its global headquarters in New York City’s Hudson Yards. Planned uses of new capital include accelerating platform and content investment, international expansion, and scaling global customer support.

Participated · Equity · Mar 2026

Candid Therapeutics is advancing a pipeline of bispecific T-cell engager (TCE) antibodies that selectively direct T cells to eliminate disease-causing B cells and plasma cells in autoimmune disorders. Its lead candidate, cizutamig, targets BCMA and CD3 and has been administered to 87 patients (47 with autoimmune diseases), showing favorable tolerability with only mild cytokine release syndrome; Phase 2 studies in myasthenia gravis and rheumatologic interstitial lung disease are slated for 2026. Additional assets include CND261, a CD20-directed TCE already tested in over 100 patients, and CND319, a dual CD19/CD20 engager expected to enter first-in-human trials in mid-2026, plus a preclinical BCMA/CD19 program. The company is led by Chairman, President and CEO Dr. Ken Song and, following a planned merger with Rallybio, will trade on Nasdaq under the ticker CDRX. An oversubscribed private financing of more than $505 million, together with Rallybio’s cash, will leave the combined entity with roughly $700 million at closing, providing funding runway through 2030. These resources are earmarked to advance multiple clinical milestones, including the Phase 2 trials for cizutamig and early-stage studies for next-generation TCEs.